WI Harper backed RWDC Industries raises US $133 Million in Series B funding round. The financing was co-led by Vickers Venture Partners, Flint Hills Resources, CPV/CAP Pensionskasse Coop, and International SA. RWDC Industries previously raised its Series A3 round in 2019, supported by WI Harper Group, Vickers Venture Partners, Eversource Retirement Plan Master Trust, and other investors.
Founded in 2015, RWDC Industries is a Singapore-headquartered biotech start-up which has developed the world’s first high yield and high purity PHA emulsion coating while achieving low cost and commercial scale. The company’s mission is to replace one-time use plastic with fully biodegradable materials.
Harnessing nature to battle the world’s single-use plastics problem, biotech company will accelerate plans to meet increasing demand for better materials to replace plastics for food service, food packaging, consumer goods packaging and other consumer items
ATHENS, GEORGIA and SINGAPORE (May 5, 2020) – RWDC Industries Limited, a Singapore-based biotech start-up providing a solution to the world’s single-use plastic crisis, announced today the closing of a US$133 million two-stage Series B funding round.
This announcement comes as the need to replace single-use plastic continues to rise to meet growing consumer demand for better materials choices. The increasing need for materials that enable greater food safety, better stewardship of the environment, and that enable a sustainable circular economy are also being driven by regulatory demands from state, local, and federal governments across the globe.
Co-founded by CEO Dr. Daniel Carraway and Executive Chairman Roland Wee, RWDC develops innovative and cost-effective biopolymer material solutions – including, polyhydroxyalkanoates or PHAs. PHAs are naturally produced by microbial fermentation of plant-based oils or sugars and are recognized as the only commercially viable biodegradable bioplastic. Primarily produced today from used cooking oil, RWDC’s PHA is certified by TÜV AUSTRIA to be fully biodegradable in soil, water, and marine conditions – leaving no toxic residue. PHA will help to improve the climate, with less GHG emissions. It will also improve human health and the health of our ecosystems, with no endocrine disrupting chemicals and no harmful micro-plastic waste. In 2018, RWDC’s proposal to use PHA to start replacing single-use plastics won the inaugural Liveability Challenge, presented by Temasek Foundation.
“We are grateful and excited to have the support of world-class investors who share our urgent mission of solving the global challenge of single-use plastic,” said Carraway, who is based in Athens, GA. “This investment will help us significantly increase our production capacity so that we can meet needs of brand owners who want to improve the lives of their customers by offering materials that have a positive effect on human health, while improving environmental stewardship.”
“We have had a global view of the plastic crisis since our founding,” said Wee, who is based in Singapore. “Consistent with that, we’ve planted a flag in both Asia and the United States, and we look forward to expanding our manufacturing of this innovative solution in Georgia. Right now, the COVID-19 pandemic presents an unprecedented crisis, but we also recognize that, for many years, we’ve been headed toward an existential threat to our individual health and our planet due to pervasive and mounting plastic pollution. It must be addressed immediately and with a solution at industrial scale. That’s what RWDC can do.”
Other participating investors include existing investors Eversource Retirement Plan Master Trust (the pension fund of Eversource Energy, a Fortune 500 company); and WI Harper Group(a pioneer of US-Asia cross-border VC investing).
“RWDC exemplifies the kind of company we support – passionate about problem solving and creating positive social impact. We believe RWDC has the potential to make an enormous difference in solving the global plastics problem, and we’re proud to continue supporting the company and its leadership,” said Dr. Finian Tan, Founder and Chairman of Vickers Venture Partners.
RWDC will use the funding to meet growing demand for PHA, including by expanding the company’s production capacity with a new facility in Athens, Georgia. Reflecting RWDC’s own mission of creating a sustainable, earth-friendly solution to plastics pollution, RWDC is repurposing an idled factory originally constructed in the late 1960s to use as its new production facility in Athens, which will bring 200 new jobs to the community in northeastern Georgia. RWDC will also use the new funds to conduct research and development efforts.
“RWDC Industries is a perfect example of Georgians’ creative approach to solving problems and finding great success, thanks in part to state resources like our public university system,” said Georgia Governor Brian Kemp. “It’s great to see a Georgia company continue to find ways to make a difference and create innovative opportunities for hardworking Georgians.”
| About RWDC Industries Limited
Based in Singapore and founded in 2015 by Mr. Roland Wee and Dr. Daniel Carraway, RWDC Industries Limited is a biotechnology company that develops innovative and cost-effective biopolymer material solutions, including polyhydroxyalkanoate (PHA). PHA is fully biodegradable and can be used as a substitute for plastic in a wide range of everyday, single-use consumer goods, from straws to utensils to cups and plates to lids. RWDC supports sustainable practices and encourages responsible choice in plastic waste management, including recycling, to protect our environment and planet.
| About WI Harper Group
Founded in 1993, WI Harper is a pioneer and leading cross-border venture capital firm investing in early and expansion stage companies across Greater China, Asia Pacific and the US. With offices in Beijing, Taipei, and San Francisco, the firm actively oversees more than $1 billion in assets under management. Since inception nearly three decades ago, WI Harper has invested in over 400 startups and has successfully experienced more than 100 IPO and M&A exits.
We look for innovative companies and visionary founders in healthcare and technology fields where there are high synergies and meaningful value added cross selling opportunities. While our healthcare team is presently focused on bioinformatics as well as digital biology, our technology team has a more generalist approach covering big data, analytics, artificial intelligence, AR/VR, IoT, robotics, drones, autonomous driving, as well as digital media and green energy projects.